Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus

Denali Therapeutics (DNLI) reported a first-quarter 2025 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. The company reported a loss of 68 cents in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The loss per share deteriorated year over year due to an increase in total operating expenses.In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations. Denali did not generate coll ...